RCC
MCID: RNL114
MIFTS: 62

Renal Cell Carcinoma, Nonpapillary (RCC)

Categories: Cancer diseases, Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Renal Cell Carcinoma, Nonpapillary

MalaCards integrated aliases for Renal Cell Carcinoma, Nonpapillary:

Name: Renal Cell Carcinoma, Nonpapillary 57 29 6
Renal Cell Carcinoma 57 38 12 76 53 75 37 15 73
Adenocarcinoma of Kidney 57 12 53 75
Hypernephroma 57 12 75
Rcc 57 12 75
Hereditary Clear Cell Renal Cell Carcinoma 59 73
Renal Carcinoma, Chromophobe, Somatic 57 13
Nonpapillary Renal Cell Carcinoma 12 15
Carcinoma, Renal Cell 44 40
Hereditary Clear Cell Renal Cell Adenocarcinoma 59
Renal Cell Carcinoma, Clear Cell, Somatic 57
Conventional Renal Cell Carcinoma 73
Carcinoma, Renal Cell, Nonpapillary 40
Renal Cell Carcinoma Non-Papillary 75
Conventional Renal Cell Carcinoma 75
Renal Cell Carcinoma, Somatic 57
Common Renal Cell Carcinoma 75
Clear Cell Renal Carcinoma 75
Renal Cell Adenocarcinoma 53
Carcinoma Renal Cell 55
Ccrcc 75
Crcc 75

Characteristics:

Orphanet epidemiological data:

59

HPO:

32
renal cell carcinoma, nonpapillary:
Inheritance sporadic


Classifications:

Orphanet: 59  
Rare renal diseases


External Ids:

OMIM 57 144700
Disease Ontology 12 DOID:0050387 DOID:4450
MeSH 44 D002292
NCIt 50 C9385
SNOMED-CT 68 41607009
Orphanet 59 ORPHA422526
ICD10 via Orphanet 34 C64
KEGG 37 H00021
SNOMED-CT via HPO 69 702391001

Summaries for Renal Cell Carcinoma, Nonpapillary

OMIM : 57 The Heidelberg histologic classification of renal cell tumors subdivides renal cell tumors into benign and malignant parenchymal neoplasms and, where possible, limits each subcategory to the most common documented genetic abnormalities (Kovacs et al., 1997). Malignant tumors are subclassified into common or conventional renal cell carcinoma (clear cell); papillary renal cell carcinoma; chromophobe renal cell carcinoma; collecting duct carcinoma, with medullary carcinoma of the kidney; and unclassified renal cell carcinoma. The common or conventional type accounts for about 75% of renal cell neoplasms and is characterized genetically by a highly specific deletion of chromosome 3p. Papillary renal cell carcinoma (see 605074) accounts for about 10% of renal cell tumors. Chromophobe renal cell carcinoma accounts for approximately 5% of renal cell neoplasms. Genetically, chromophobe RCC is characterized by a combination of loss of heterozygosity of chromosomes 1, 2, 6, 10, 13, 17, and 21 and hypodiploid DNA content. Collecting duct carcinoma accounts for about 1% of renal cell carcinoma. Renal cell carcinoma occurs nearly twice as often in men as in women; incidence in the United States is equivalent among whites and blacks. Cigarette smoking doubles the likelihood of renal cell carcinoma and contributes to as many as one-third of cases. Obesity is also a risk factor, particularly in women. Other risk factors include hypertension, unopposed estrogen therapy, and occupational exposure to petroleum products, heavy metals, or asbestos (summary by Motzer et al., 1996). (144700)

MalaCards based summary : Renal Cell Carcinoma, Nonpapillary, also known as renal cell carcinoma, is related to hereditary renal cell carcinoma and clear cell papillary renal cell carcinoma, and has symptoms including flank pain An important gene associated with Renal Cell Carcinoma, Nonpapillary is RNF139 (Ring Finger Protein 139), and among its related pathways/superpathways are Renal cell carcinoma and Transcriptional misregulation in cancer. The drugs Afinitor and Avastin have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and lung, and related phenotype is renal cell carcinoma.

Disease Ontology : 12 A renal carcinoma that has material basis in the lining of the proximal convoluted renal tubule of the kidney.

UniProtKB/Swiss-Prot : 75 Renal cell carcinoma: Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into clear cell renal carcinoma (non- papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma. Clear cell renal cell carcinoma is the most common subtype.

Wikipedia : 76 Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted... more...

Related Diseases for Renal Cell Carcinoma, Nonpapillary

Diseases related to Renal Cell Carcinoma, Nonpapillary via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 568)
# Related Disease Score Top Affiliating Genes
1 hereditary renal cell carcinoma 34.2 RNF139 FLCN FHIT
2 clear cell papillary renal cell carcinoma 34.0 VHL HNF1A
3 chromophobe renal cell carcinoma 33.2 HNF1B HNF1A FLCN
4 kidney cancer 33.1 VHL PVT1 MIR200C MIR141 MALAT1 FLCN
5 clear cell renal cell carcinoma 32.9 VHL SETD2 RNF139 PVT1 PANDAR OGG1
6 cholangiocarcinoma 30.6 PANDAR OGG1 MIR141 MALAT1 FHIT
7 gastric cancer 30.4 PVT1 PANDAR MIR200C MIR141 MALAT1 FHIT
8 lung cancer 30.4 PVT1 PANDAR OGG1 MIR200C MIR141 MALAT1
9 colorectal cancer 30.2 FHIT FLCN MALAT1 MIR141 MIR200C OGG1
10 bladder urothelial carcinoma 30.1 PVT1 MALAT1 FHIT
11 pancreatic ductal adenocarcinoma 30.1 PVT1 MIR141 MALAT1
12 osteogenic sarcoma 30.0 PVT1 PANDAR MALAT1
13 eosinophilic variant of chromophobe renal cell carcinoma 12.3
14 multilocular clear cell renal cell carcinoma 12.3
15 renal cell carcinoma associated with neuroblastoma 12.3
16 renal cell carcinoma 4 12.2
17 mucinous tubular and spindle renal cell carcinoma 12.1
18 hereditary conventional renal cell carcinoma 12.1
19 hereditary leiomyomatosis and renal cell cancer 12.1
20 classic variant of chromophobe renal cell carcinoma 12.1
21 melanoma, cutaneous malignant 8 11.7
22 childhood kidney cell carcinoma 11.6
23 multilocular cystic renal neoplasm of low malignant potential 11.5
24 von hippel-lindau syndrome 11.5
25 renal cell carcinoma, papillary, 1 11.4
26 tuberous sclerosis 1 11.4
27 metanephric adenoma 11.3
28 birt-hogg-dube syndrome 11.3
29 thyroid carcinoma, papillary, with papillary renal neoplasia 11.1
30 chromophil renal cell carcinoma 11.1
31 renal cell carcinoma, xp11-associated 11.0
32 cowden syndrome 1 11.0
33 tumor predisposition syndrome 11.0
34 cowden syndrome 4 11.0
35 cowden syndrome 5 11.0
36 cowden syndrome 6 11.0
37 cowden syndrome 7 11.0
38 bap1 tumor predisposition syndrome 11.0
39 angiomyolipoma 10.6
40 leiomyomatosis 10.5
41 kidney disease 10.5
42 adamantinoma of long bones 10.4 PVT1 PANDAR MIR200C MIR141 MALAT1 FHIT
43 tuberous sclerosis 10.4
44 ovarian serous carcinoma 10.4 MIR200C MIR141
45 maturity-onset diabetes of the young, type 4 10.4 HNF1B HNF1A
46 oncocytoma 10.4
47 maturity-onset diabetes of the young, type 2 10.4 HNF1B HNF1A
48 microvascular complications of diabetes 3 10.4 PVT1 MALAT1
49 maturity-onset diabetes of the young, type 3 10.3 HNF1B HNF1A
50 kidney angiomyolipoma 10.3

Graphical network of the top 20 diseases related to Renal Cell Carcinoma, Nonpapillary:



Diseases related to Renal Cell Carcinoma, Nonpapillary

Symptoms & Phenotypes for Renal Cell Carcinoma, Nonpapillary

Clinical features from OMIM:

144700

Human phenotypes related to Renal Cell Carcinoma, Nonpapillary:

32
# Description HPO Frequency HPO Source Accession
1 renal cell carcinoma 32 HP:0005584

UMLS symptoms related to Renal Cell Carcinoma, Nonpapillary:


flank pain

Drugs & Therapeutics for Renal Cell Carcinoma, Nonpapillary

FDA approved drugs:

(show all 7)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Afinitor 18 49 EVEROLIMUS Novartis March 2009
2
Avastin 18 49 BEVACIZUMAB Genentech July 2009
3
Inlyta 18 49 AXITINIB Pfizer January 2012
4
Nexavar 18 49 SORAFENIB TOSYLATE Bayer/Onyx December 2005
5
Sutent 18 49 SUNITINIB MALATE Pfizer May 2011/ January 2006
6
Torisel 18 49 TEMSIROLIMUS Wyeth May 2007
7
Votrient 18 49 PAZOPANIB HYDROCHLORIDE GlaxoSmithKline April 2012/ October of 2009

Drugs for Renal Cell Carcinoma, Nonpapillary (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 189)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
2
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 557795-19-4, 341031-54-7 5329102
3
Aldesleukin Approved Phase 4,Phase 2,Phase 1,Early Phase 1 85898-30-2, 110942-02-4
4
Nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 946414-94-4
5 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
6 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
7 Anti-HIV Agents Phase 4,Phase 2,Phase 1,Early Phase 1
8 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
9 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Anti-Retroviral Agents Phase 4,Phase 2,Phase 1,Early Phase 1
11 Interleukin-2 Phase 4,Phase 2,Phase 1,Early Phase 1
12 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Analgesics Phase 4,Phase 2,Phase 1,Early Phase 1
14 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1,Early Phase 1
15 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 1,Early Phase 1
16 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19
Everolimus Approved Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 6442177
20
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 46835353 6436030 5284616
21
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
22
Sorafenib Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 284461-73-0 216239 406563
23
Iodine Approved, Investigational Phase 3 7553-56-2 807
24
Axitinib Approved, Investigational Phase 3,Phase 2,Phase 1 319460-85-0 6450551
25 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
26 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
27 Antifungal Agents Phase 3,Phase 2,Phase 1,Not Applicable
28 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
29 Interferon-alpha Phase 3,Phase 2,Phase 1
30 interferons Phase 3,Phase 2,Phase 1
31 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
32 Micronutrients Phase 3,Phase 2,Phase 1,Not Applicable
33 Anti-Infective Agents, Local Phase 3
34 cadexomer iodine Phase 3
35 Trace Elements Phase 3,Phase 2,Phase 1,Not Applicable
36 Immunoconjugates Phase 3,Phase 1
37 tyrosine Phase 3,Phase 2,Phase 1
38 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Immunoglobulin G Phase 3,Phase 1,Phase 2,Early Phase 1
40 Endothelial Growth Factors Phase 3,Phase 2,Phase 1,Early Phase 1
41 Mitogens Phase 3,Phase 2,Phase 1,Early Phase 1
42
Tinzaparin Approved Phase 1, Phase 2 9005-49-6, 9041-08-1 25244225
43
Heparin Approved, Investigational Phase 1, Phase 2 9005-49-6 772 46507594
44
Dalteparin Approved Phase 1, Phase 2 9005-49-6
45
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
46
Panobinostat Approved, Investigational Phase 2,Phase 1 404950-80-7 6918837
47
Denosumab Approved Phase 2 615258-40-7
48
Pembrolizumab Approved Phase 2,Phase 1 1374853-91-4
49
leucovorin Approved Phase 2 58-05-9 6006 143
50
Levoleucovorin Approved, Investigational Phase 2 68538-85-2

Interventional clinical trials:

(show top 50) (show all 208)
# Name Status NCT ID Phase Drugs
1 Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy Active, not recruiting NCT02570789 Phase 4 patients with sunitinib or pazopanib
2 Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
3 Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed NCT00006864 Phase 4
4 A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer Active, not recruiting NCT02982954 Phase 4 Nivolumab;Ipilimumab
5 Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) Active, not recruiting NCT01668784 Phase 3 Everolimus
6 Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody Completed NCT00606632 Phase 3 124-Iodine-cG250 (124I-cG250)
7 REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT Withdrawn NCT01762592 Phase 3 Iodine (124I) Girentuximab
8 TroVax Renal Immunotherapy Survival Trial Completed NCT00397345 Phase 3
9 Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients Terminated NCT01599754 Phase 3 Axitinib;Placebo
10 Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma Completed NCT02883153 Phase 2, Phase 3 Zirconium-89 girentuximab PET/CT
11 A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy Completed NCT00738530 Phase 3 Bevacizumab [Avastin];Interferon alfa 2a [Roferon];Placebo
12 Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Active, not recruiting NCT01575548 Phase 3 Pazopanib Hydrochloride
13 Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer Active, not recruiting NCT01099423 Phase 3
14 Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Terminated NCT01198158 Phase 3 Everolimus
15 Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer) Completed NCT00072046 Phase 3
16 Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer Completed NCT00087022 Phase 3
17 S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Active, not recruiting NCT01120249 Phase 3 everolimus
18 Nivolumab and Ipilimumab Followed by Nivolumab Versus Cabozantinib and Nivolumab in Treating Patients With Metastatic Untreated Renal Cell Cancer Not yet recruiting NCT03793166 Phase 3 Cabozantinib
19 Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer Completed NCT00492258 Phase 3 sorafenib tosylate
20 Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC) Unknown status NCT01069770 Phase 2 Sunitinib
21 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC Unknown status NCT01791387 Phase 2 Dovitinib
22 Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT) Unknown status NCT01216371 Phase 2 Sunitinib;Placebo
23 Sequential Therapy With Bevacizumab, RAd001 (Everolimus) and Tyrosinekinase Inhibitors (TKI) in Metastatic Renal Cell Carinoma (mRCC) Unknown status NCT01731158 Phase 2 Avastin in combination with Roferon-A;Afinitor;Sutent, Nexavar or Votrient
24 Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery Unknown status NCT00293501 Phase 1, Phase 2 tinzaparin sodium
25 Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Unknown status NCT00301990 Phase 2
26 Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma Recruiting NCT03680521 Phase 2 Sitravatinib;Nivolumab
27 Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA Completed NCT02607553 Phase 2 G-202
28 Diagnostic Imaging for Clear Cell Renal Cell Carcinoma Recruiting NCT03185182 Phase 2 Ioflupane I123
29 Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma Recruiting NCT02781506 Phase 2 Nivolumab
30 LBH589 Treatment for Refractory Clear Cell Renal Carcinoma Completed NCT00550277 Phase 2 LBH589
31 Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney Completed NCT00853021 Phase 2
32 PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma Active, not recruiting NCT03108066 Phase 2 PT2385 Tablets
33 Vandetanib to Treat Advanced Kidney Cancer Terminated NCT01372813 Phase 2 vandetanib
34 Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma Recruiting NCT03280667 Phase 2 Pembrolizumab plus denosumab
35 Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma Completed NCT00729053 Phase 2 IMO-2055
36 Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment. Recruiting NCT03066427 Phase 2 Sunitinib
37 Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) Active, not recruiting NCT01392183 Phase 2 Pazopanib;Temsirolimus;Benadryl
38 MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Active, not recruiting NCT02724020 Phase 2 Everolimus;MLN0128;MLN1117
39 High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer Active, not recruiting NCT01896271 Phase 2 IL-2
40 BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Completed NCT01034631 Phase 1, Phase 2 Everolimus;BNC105P
41 Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma Withdrawn NCT00293527 Phase 2 Interferon Alpha-2b
42 BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas Recruiting NCT03355976 Phase 2 Nivolumab;Ipilimumab
43 GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma Completed NCT00244764 Phase 2 GW786034;Placebo
44 A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC). Completed NCT00796757 Phase 2 bevacizumab [Avastin];interferon alfa-2a
45 Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib Recruiting NCT03592199 Phase 2 Sunitinib
46 A Trial of PT2977 in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) Recruiting NCT03634540 Phase 2 PT2977 in combination with cabozantinib tablets
47 Addition of X4P-001 to Nivolumab Treatment in Patients With Renal Cell Carcinoma Completed NCT02923531 Phase 1, Phase 2 X4P-001;Nivolumab
48 AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib Completed NCT00467025 Phase 2 AMG 386;Sorafenib;AMG 386 placebo IV
49 Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer Recruiting NCT02989714 Phase 1, Phase 2 Interleukin-2;Nivolumab
50 BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC) Active, not recruiting NCT01354431 Phase 2

Search NIH Clinical Center for Renal Cell Carcinoma, Nonpapillary

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: carcinoma, renal cell

Genetic Tests for Renal Cell Carcinoma, Nonpapillary

Genetic tests related to Renal Cell Carcinoma, Nonpapillary:

# Genetic test Affiliating Genes
1 Renal Cell Carcinoma, Nonpapillary 29 FLCN HNF1A HNF1B OGG1 RNF139 SLC49A4 VHL

Anatomical Context for Renal Cell Carcinoma, Nonpapillary

MalaCards organs/tissues related to Renal Cell Carcinoma, Nonpapillary:

41
Kidney, Endothelial, Lung, Bone, T Cells, Brain, Thyroid

Publications for Renal Cell Carcinoma, Nonpapillary

Articles related to Renal Cell Carcinoma, Nonpapillary:

(show top 50) (show all 7334)
# Title Authors Year
1
Concomitant perinephric Castleman disease and renal cell carcinoma initially suspected to be metastasis: A case report and 24 months follow up. ( 30479965 )
2019
2
A rare case of tumor-to-tumor metastasis: Prostate cancer to chromophobe renal cell carcinoma. ( 30505689 )
2019
3
Successful partial nephrectomy of a T1b multilocular clear cell renal cell carcinoma arising in a renal graft. ( 30345224 )
2019
4
Expression and epigenetic regulatory mechanism of BNIP3 in clear cell renal cell carcinoma. ( 30365137 )
2019
5
MicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinoma. ( 30183478 )
2019
6
Phosphoinositide-dependent kinase 1-associated glycolysis is regulated by miR-409-3p in clear cell renal cell carcinoma. ( 30218446 )
2019
7
Tumor-infiltrating neutrophils predict therapeutic benefit of tyrosine kinase inhibitors in metastatic renal cell carcinoma. ( 30546957 )
2019
8
Re: Below Safety Limits, Every Unit of Glomerular Filtration Rate Counts: Assessing the Relationship between Renal Function and Cancer-specific Mortality in Renal Cell Carcinoma. ( 30425009 )
2019
9
Delayed brain metastasis from renal cell carcinoma. ( 30425927 )
2019
10
VEGI174 protein and its functional domain peptides exert antitumour effects on renal cell carcinoma. ( 30431089 )
2019
11
Trends and outcomes of lymphadenectomy for nonmetastatic renal cell carcinoma: A propensity score-weighted analysis of the National Cancer Database. ( 30446458 )
2019
12
Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. ( 30467042 )
2019
13
Polymorphism rs4787951 in IL-4R contributes to the increased risk of renal cell carcinoma in a Chinese population. ( 30472377 )
2019
14
Immune-related lichenoid mucocutaneous erosions during anti-PD-1 immunotherapy in metastatic renal cell carcinoma - A case report. ( 30505683 )
2019
15
MicroRNA‑222‑3p promotes tumor cell migration and invasion and inhibits apoptosis, and is correlated with an unfavorable prognosis of patients with renal cell carcinoma. ( 30320376 )
2019
16
Boiling Histotripsy Ablation of Renal Cell Carcinoma in the Eker Rat Promotes a Systemic Inflammatory Response. ( 30340920 )
2019
17
Renal cell carcinoma presenting as epistaxis from a nasal cavity metastasis. ( 30386450 )
2019
18
Prolonged survival of renal cancer patients is concomitant with a higher regucalcin gene expression in tumor tissues: Overexpression of regucalcin suppresses the growth of human renal cell carcinoma cells in vitro. ( 30387835 )
2019
19
MicroRNA-363 inhibits angiogenesis, proliferation, invasion, and migration of renal cell carcinoma via inactivation of the Janus tyrosine kinases 2-signal transducers and activators of transcription 3 axis by suppressing growth hormone receptor gene. ( 30229899 )
2019
20
Expression of vitamin D receptor in clear cell papillary renal cell carcinoma. ( 29966830 )
2018
21
Diagnostic Accuracy of Unenhanced CT Analysis to Differentiate Low-Grade From High-Grade Chromophobe Renal Cell Carcinoma. ( 29547054 )
2018
22
Unusual progression of renal cell carcinoma with carcinomatosis peritoneii and Krukenberg tumour and alopecia with sunitinib therapy in young female. ( 29409504 )
2018
23
Wilms' tumor 1-associating protein promotes renal cell carcinoma proliferation by regulating CDK2 mRNA stability. ( 29482572 )
2018
24
Involvement of transforming growth factor beta 1 in the transcriptional regulation of nicotinamide N-methyltransferase in clear cell renal cell carcinoma. ( 29974846 )
2018
25
Next-Generation Sequencing to Detect Deletion of RB1 and ERBB4 Genes in Chromophobe Renal Cell Carcinoma: A Potential Role in Distinguishing Chromophobe Renal Cell Carcinoma from Renal Oncocytoma. ( 29353061 )
2018
26
Extensive Metastatic Sarcomatoid Renal Cell Carcinoma Evaluated by<sup>18</sup>F-FDG PET/CT: a Case Report and Review of Literature. ( 29354391 )
2018
27
Preclinical studies using miR-32-5p to suppress clear cell renal cell carcinoma metastasis via altering the miR-32-5p/TR4/HGF/Met signaling. ( 29396852 )
2018
28
Leptin and its receptor: can they help to differentiate chromophobe renal cell carcinoma from renal oncocytoma? ( 29970253 )
2018
29
Prognostic value of D-lactate dehydrogenase in patients with clear cell renal cell carcinoma. ( 29963157 )
2018
30
Biallelic <i>TSC2</i> Mutations in a Patient With Chromophobe Renal Cell Carcinoma Showing Extraordinary Response to Temsirolimus. ( 29632054 )
2018
31
Fine-needle aspiration of tubulocystic renal cell carcinoma. ( 29624918 )
2018
32
Vascular Endothelial Growth Factor Inhibitor Therapy and Cardiovascular and Renal Damage in Renal Cell Carcinoma. ( 28676023 )
2018
33
Complete Response of a Patient With Metastatic Sarcomatoid Renal Cell Carcinoma to a Programmed Death-1 Checkpoint Inhibitor. ( 29920137 )
2018
34
Noncoding RNA Expression and Targeted Next-Generation Sequencing Distinguish Tubulocystic Renal Cell Carcinoma (TC-RCC) from Other Renal Neoplasms. ( 29056573 )
2018
35
Pattern multiplicity and fumarate hydratase (FH)/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas from kidney tumors without FH gene alteration. ( 29410489 )
2018
36
Emerging entities in renal cell neoplasia: thyroid-like follicular renal cell carcinoma and multifocal oncocytoma-like tumours associated with oncocytosis. ( 29132724 )
2018
37
Rare and changeable as a chameleon: paraneoplastic syndromes in renal cell carcinoma. ( 29429069 )
2018
38
Influence of Contrast Administration on Computed Tomography-Based Analysis of Visceral Adipose and Skeletal Muscle Tissue in Clear Cell Renal Cell Carcinoma. ( 29350403 )
2018
39
Clinical features and survival analysis of clear cell papillary renal cell carcinoma: A 10-year retrospective study from two institutions. ( 29963177 )
2018
40
Clear cell renal cell carcinoma: identifying PTEN expression on multiphasic MDCT. ( 29946925 )
2018
41
Sarcomatoid renal cell carcinoma: Biology and treatment advances. ( 29306556 )
2018
42
Highlights in renal cell carcinoma from the Sixteenth International Kidney Cancer Symposium: commentary. ( 29742094 )
2018
43
Variation in nuclear size and PD-L2 positivity correlate with aggressive chromophobe renal cell carcinoma. ( 29661724 )
2018
44
Acquired Cystic Disease-associated Renal Cell Carcinoma (ACD-RCC): A Multiinstitutional Study of 40 Cases With Clinical Follow-up. ( 29851703 )
2018
45
Genetic and metabolic hallmarks of clear cell renal cell carcinoma. ( 29959988 )
2018
46
Case - Laparoscopic transperitoneal partial nephrectomy of T3a renal cell carcinoma within a horseshoe kidney. ( 29405905 )
2018
47
SREBP1-driven lipid desaturation supports clear cell renal cell carcinoma growth through regulation of NF-I_B signaling. ( 29183723 )
2018
48
Correction to: Reassessing the clinical spectrum associated with Hereditary Leiomyomatosis and Renal Cell Carcinoma syndrome in French FH mutation carriers. ( 29655270 )
2018
49
A back-to-back tumor composed of papillary renal cell carcinoma and oncocytoma treated by laparoscopic partial nephrectomy: a case report. ( 29779490 )
2018
50
Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma. ( 29357836 )
2018

Variations for Renal Cell Carcinoma, Nonpapillary

UniProtKB/Swiss-Prot genetic disease variations for Renal Cell Carcinoma, Nonpapillary:

75
# Symbol AA change Variation ID SNP ID
1 FLCN p.Arg239Cys VAR_066026 rs78683075
2 SETD2 p.Asn1733Asp VAR_069812
3 SETD2 p.Ser1769Pro VAR_069813
4 VHL p.Leu163Pro VAR_034998 rs28940297

ClinVar genetic disease variations for Renal Cell Carcinoma, Nonpapillary:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 OGG1 NM_016821.2(OGG1): c.1043G> A (p.Gly348Glu) single nucleotide variant Likely benign rs41276495 GRCh37 Chromosome 3, 9807587: 9807587
2 OGG1 NM_016821.2(OGG1): c.1043G> A (p.Gly348Glu) single nucleotide variant Likely benign rs41276495 GRCh38 Chromosome 3, 9765903: 9765903

Cosmic variations for Renal Cell Carcinoma, Nonpapillary:

9 (show top 50) (show all 2582)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM25676 VHL kidney,NS,carcinoma,renal cell c.485G>T p.C162F 3:10149808-10149808 49
2 COSM27269 UMPS kidney,NS,carcinoma,renal cell c.528G>A p.L176L 3:124737785-124737785 49
3 COSM30474 TRIO kidney,NS,carcinoma,renal cell c.9008A>G p.N3003S 5:14508136-14508136 49
4 COSM26594 RNF144A kidney,NS,carcinoma,renal cell c.410C>T p.A137V 2:7020581-7020581 49
5 COSM26987 RGS7 kidney,NS,carcinoma,renal cell c.169T>C p.F57L 1:241098672-241098672 49
6 COSM26614 RABGAP1 kidney,NS,carcinoma,renal cell c.1533T>A p.H511Q 9:123020414-123020414 49
7 COSM30530 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 1:113859066-113859066 49
8 COSM27618 KMT2A kidney,NS,carcinoma,renal cell c.5711C>T p.A1904V 11:118497991-118497991 49
9 COSM30502 ITPR3 kidney,NS,carcinoma,renal cell c.4574G>T p.C1525F 6:33682621-33682621 49
10 COSM28415 DOCK1 kidney,NS,carcinoma,renal cell c.1306G>T p.D436Y 10:127023241-127023241 49
11 COSM30531 COPS4 kidney,NS,carcinoma,renal cell c.385G>C p.G129R 4:83049959-83049959 49
12 COSM25654 CDC5L kidney,NS,carcinoma,renal cell c.1196G>A p.R399Q 6:44419552-44419552 49
13 COSM30471 ARHGAP20 kidney,NS,carcinoma,renal cell c.1355A>G p.D452G 11:110586276-110586276 49
14 COSM6941466 XIAP kidney,NS,carcinoma,renal cell carcinoma c.563G>C p.G188A 23:123886225-123886225 44
15 COSM14312 VHL kidney,NS,carcinoma,renal cell carcinoma c.353T>C p.L118P 3:10146526-10146526 44
16 COSM17957 VHL kidney,NS,carcinoma,renal cell carcinoma c.292T>G p.Y98D 3:10142139-10142139 44
17 COSM14382 VHL kidney,NS,carcinoma,renal cell carcinoma c.245G>C p.R82P 3:10142092-10142092 44
18 COSM6957851 TSC2 kidney,NS,carcinoma,renal cell carcinoma c.541G>A p.V181M 16:2055461-2055461 44
19 COSM6942356 TSC1 kidney,NS,carcinoma,renal cell carcinoma c.2287C>T p.Q763* 9:132902709-132902709 44
20 COSM6963117 TSC1 kidney,NS,carcinoma,renal cell carcinoma c.1001C>A p.S334* 9:132911481-132911481 44
21 COSM29770 TSC1 kidney,NS,carcinoma,renal cell carcinoma c.508+1G>T p.? 9:132923347-132923347 44
22 COSM10656 TP53 kidney,NS,carcinoma,renal cell carcinoma c.742C>T p.R248W 17:7674221-7674221 44
23 COSM45243 TP53 kidney,NS,carcinoma,renal cell carcinoma c.374C>G p.T125R 17:7675995-7675995 44
24 COSM44310 TP53 kidney,NS,carcinoma,renal cell carcinoma c.738G>A p.M246I 17:7674225-7674225 44
25 COSM6922197 TP53 kidney,NS,carcinoma,renal cell carcinoma c.97-2A>C p.? 17:7676274-7676274 44
26 COSM45135 TP53 kidney,NS,carcinoma,renal cell carcinoma c.673-1G>T p.? 17:7674291-7674291 44
27 COSM6929752 TBX3 kidney,NS,carcinoma,renal cell carcinoma c.510G>T p.W170C 12:114681026-114681026 44
28 COSM6979493 STAG2 kidney,NS,carcinoma,renal cell carcinoma c.2096+1G>A p.? 23:124065947-124065947 44
29 COSM6975582 STAG2 kidney,NS,carcinoma,renal cell carcinoma c.1348A>T p.R450* 23:124057909-124057909 44
30 COSM6023628 STAG2 kidney,NS,carcinoma,renal cell carcinoma c.2860C>T p.R954C 23:124081464-124081464 44
31 COSM6963119 SPOP kidney,NS,carcinoma,renal cell carcinoma c.265T>G p.L89V 17:49619321-49619321 44
32 COSM989 SMARCB1 kidney,NS,carcinoma,renal cell carcinoma c.1130G>A p.R377H 22:23834152-23834152 44
33 COSM6964939 SMARCB1 kidney,NS,carcinoma,renal cell carcinoma c.987-2A>T p.? 22:23833570-23833570 44
34 COSM1266238 SMARCA4 kidney,NS,carcinoma,renal cell carcinoma c.3575G>A p.R1192H 19:11033318-11033318 44
35 COSM6947611 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.863C>A p.S288* 3:47122264-47122264 44
36 COSM6975580 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.4736C>G p.S1579* 3:47062211-47062211 44
37 COSM4118007 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.3266G>A p.R1089Q 3:47106061-47106061 44
38 COSM4794860 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.5922+1G>A p.? 3:47019759-47019759 44
39 COSM6925125 RBM10 kidney,NS,carcinoma,renal cell carcinoma c.179C>A p.S60* 23:47169476-47169476 44
40 COSM6922201 RBM10 kidney,NS,carcinoma,renal cell carcinoma c.299G>C p.G100A 23:47171125-47171125 44
41 COSM6947629 PTCH1 kidney,NS,carcinoma,renal cell carcinoma c.3616C>T p.R1206C 9:95449257-95449257 44
42 COSM6927541 PRKN kidney,NS,carcinoma,renal cell carcinoma c.629T>G p.F210C 6:161973407-161973407 44
43 COSM6913448 POLE kidney,NS,carcinoma,renal cell carcinoma c.4735C>T p.R1579C 12:132642723-132642723 44
44 COSM6972882 PMS1 kidney,NS,carcinoma,renal cell carcinoma c.572T>A p.V191E 2:189818170-189818170 44
45 COSM6923488 PIM1 kidney,NS,carcinoma,renal cell carcinoma c.101T>A p.L34Q 6:37170791-37170791 44
46 COSM6969911 PIK3CG kidney,NS,carcinoma,renal cell carcinoma c.2039T>A p.F680Y 7:106872580-106872580 44
47 COSM763 PIK3CA kidney,NS,carcinoma,renal cell carcinoma c.1633G>A p.E545K 3:179218303-179218303 44
48 COSM6921803 PIK3C2G kidney,NS,carcinoma,renal cell carcinoma c.3493T>C p.F1165L 12:18562728-18562728 44
49 COSM6922195 PIK3C2G kidney,NS,carcinoma,renal cell carcinoma c.1986G>C p.Q662H 12:18391235-18391235 44
50 COSM6918100 PBRM1 kidney,NS,carcinoma,renal cell carcinoma c.1183A>C p.S395R 3:52634720-52634720 44

Copy number variations for Renal Cell Carcinoma, Nonpapillary from CNVD:

7 (show top 50) (show all 1298)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14830 1 1104523 1105523 Gain Renal cell carcinoma
2 16766 1 13658511 13659511 Gain Renal cell carcinoma
3 16770 1 13703176 13704176 Loss Renal cell carcinoma
4 16773 1 13722829 13723829 Gain Renal cell carcinoma
5 19216 1 14925199 15393109 Loss Renal cell carcinoma
6 24428 1 180300000 185800000 Copy number Renal cell carcinoma
7 26325 1 199103044 199104044 Gain Renal cell carcinoma
8 27335 1 207179162 207180162 Gain Renal cell carcinoma
9 27861 1 214500000 224100000 Gain Renal cell carcinoma
10 30088 1 24000000 26000000 Loss Renal cell carcinoma
11 31042 1 24862824 24867531 Loss RCAN3 Renal cell carcinoma
12 31527 1 28000000 30200000 Loss Renal cell carcinoma
13 33893 1 5000000 7000000 Loss Renal cell carcinoma
14 42189 10 3000000 17300000 Copy number Renal cell carcinoma
15 42932 10 42300000 52900000 Copy number Renal cell carcinoma
16 49432 11 106916419 134173875 Loss Renal cell carcinoma
17 49705 11 110400000 121200000 Copy number Renal cell carcinoma
18 51840 11 13182721 13183721 Gain Renal cell carcinoma
19 51843 11 13184856 13185856 Loss Renal cell carcinoma
20 52861 11 21000000 57000000 Gain Renal cell carcinoma
21 53056 11 23642584 23643584 Gain Renal cell carcinoma
22 53595 11 31000000 43500000 Copy number Renal cell carcinoma
23 53953 11 35317771 35318771 Gain Renal cell carcinoma
24 60490 11 87000000 107000000 Gain Renal cell carcinoma
25 64438 12 12800000 14800000 Copy number Renal cell carcinoma
26 67031 12 35000000 69000000 Gain Renal cell carcinoma
27 67043 12 35400000 132349534 Gain Renal cell carcinoma
28 69398 12 54900000 58100000 Copy number Renal cell carcinoma
29 72532 12 82000000 100000000 Gain Renal cell carcinoma
30 75379 13 19500000 23300000 Loss Renal cell carcinoma
31 75593 13 21548578 21635655 Copy number Renal cell carcinoma
32 82801 14 15600000 106368585 Copy number Renal cell carcinoma
33 82818 14 15600000 106368585 Loss Renal cell carcinoma
34 83187 14 19387587 106241517 Loss Renal cell carcinoma
35 85229 14 41000000 48000000 Gain Renal cell carcinoma
36 87551 14 74550219 74587988 Loss MLH3 Renal cell carcinoma
37 88249 14 88692268 89155247 Loss FOXN3 Renal cell carcinoma
38 88312 14 89800000 91900000 Copy number Renal cell carcinoma
39 89170 15 100153615 100154615 Gain Renal cell carcinoma
40 90158 15 20233523 20234523 Gain Renal cell carcinoma
41 90187 15 20359182 20360182 Gain Renal cell carcinoma
42 90188 15 20359229 20360229 Gain Renal cell carcinoma
43 90209 15 20439260 20440260 Loss Renal cell carcinoma
44 90210 15 20442152 20442452 Loss Renal cell carcinoma
45 90214 15 20449913 20450913 Gain Renal cell carcinoma
46 90215 15 20450115 20451115 Loss Renal cell carcinoma
47 90218 15 20535877 20536877 Loss Renal cell carcinoma
48 90224 15 20611271 20612271 Loss Renal cell carcinoma
49 90229 15 20643792 20644792 Loss Renal cell carcinoma
50 90232 15 20666179 20666479 Loss Renal cell carcinoma

Expression for Renal Cell Carcinoma, Nonpapillary

Search GEO for disease gene expression data for Renal Cell Carcinoma, Nonpapillary.

Pathways for Renal Cell Carcinoma, Nonpapillary

Pathways related to Renal Cell Carcinoma, Nonpapillary according to KEGG:

37
# Name Kegg Source Accession
1 Renal cell carcinoma hsa05211
2 Transcriptional misregulation in cancer hsa05202

GO Terms for Renal Cell Carcinoma, Nonpapillary

Biological processes related to Renal Cell Carcinoma, Nonpapillary according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 pancreas development GO:0031016 9.16 HNF1A HNF1B
2 positive regulation of transcription initiation from RNA polymerase II promoter GO:0060261 8.96 HNF1A HNF1B
3 regulation of pronephros size GO:0035565 8.62 HNF1A HNF1B

Sources for Renal Cell Carcinoma, Nonpapillary

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....